🟢 Xenetic Biosciences is trading 6.5% up today following proposed all-stock acquisition

Xenetic Biosciences is trading 6.5% up now at $2.62 amid continued volatility following its proposed all-stock acquisition of Santersus AG.

• Santersus shareholders would own approximately 85% of the combined company, while existing Xenetic shareholders would retain about 15%.
• The transaction is expected to create Santersus Bio and close in the fourth quarter of 2026.
• The move follows a 12.33% gain on September 17 after a 48.71% decline on September 16, indicating sharp repricing around the deal.